1. Anti-infection
    Metabolic Enzyme/Protease
  2. HIV
    HIV Protease

Atazanavir (Synonyms: BMS-232632)

Cat. No.: HY-17367
Handling Instructions

Atazanavir(BMS-232632) is an highly potent HIV-1 protease inhibitor.

For research use only. We do not sell to patients.
Atazanavir Chemical Structure

Atazanavir Chemical Structure

CAS No. : 198904-31-3

Size Price Stock
10 mg USD 72 Get quote
50 mg USD 144 Get quote
100 mg USD 240 Get quote

* Please select Quantity before adding items.

Other In-stock Forms of Atazanavir:

Other Forms of Atazanavir:

  • Biological Activity

  • Protocol

  • Technical Information

  • References


Atazanavir(BMS-232632) is an highly potent HIV-1 protease inhibitor. IC50 value: Target: HIV-1 protease inhibitor Atazanavir sulfate is a sulfate salt form of atazanavir that is an highly potent HIV-1 protease inhibitor. It has a pharmacokinetic profile that supports once-daily dosing and has demonstrated a unique resistance profile and superior virologic potency compared with other antiretrovirals in vitro. In subjects with HIV, atazanavir (400 mg once daily) produced rapid and sustained improvements in viral load and CD4 counts in both antiretroviral-naive as well as previously treated patients when used in combination with dual nucleoside reverse transcriptase inhibitor (NRTI) treatment [1]. After intravenous (iv), oral (po) and intraportal (ip) administration of ATV at a dosage of 7 mg/kg, AUCs in HL rats were 12.41, 5.24 and 8.89 microg/mLh, respectively, and were significantly higher than those in control rats (4.09, 1.70 and 3.38 microg/mLh). Despite the decrease of distribution volume (Vd(ss)), the terminal half-life (t(1/2)) in HL tended to be shorter than in control, and hepatic distribution of ATV in HL rats was 4.8-fold increases. These results suggested that the uptake of ATV into liver might counteract the decrease of Vd(ss). On the other hand, there was no significant difference in bioavailability, and the lymphatic transport to AUC showed no statistical change. In conclusion, although the protein binding rate and AUC were significantly increased, the pharmacokinetics of ATV might be tolerated in HL [2]. Clinical indications: HIV-1 infection Toxicity: torsades de pointes

Clinical Trial
Molecular Weight







O=C(OC)N[[email protected]@H](C(C)(C)C)C(NN(CC1=CC=C(C2=NC=CC=C2)C=C1)C[[email protected]](O)[[email protected]](CC3=CC=CC=C3)NC([[email protected]](C(C)(C)C)NC(OC)=O)=O)=O


Please store the product under the recommended conditions in the Certificate of Analysis.


Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number *


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: